1.Sales and profit
See section β- Biovie Inc. lost $22.1M in fiscal 2026.
Biovie Inc.
BIVI Nasdaq Pharmaceutical Preparations Financials FY2017βFY2026
- Today
- 8.3%
- Previous close
- $1.33
- Market cap
- $10.4M
- P/E
- β
- Day range
-
$1.34 $1.45
- 52-week range
-
$0.96 $2.28
Last close Β· Oct 27, 2026
$1.44
β$0.45 (β23.81%) past year
KIRAβs summary AI analyst
Hi! I read Biovie Inc.βs latest annual report (fiscal 2026). Here is what stands out:
1 to watch
2.Cash and shareholders
See section β- In the last 12 months, insiders bought $0.0M of shares on the open market and sold none.
Biovie Inc. in 30 seconds
Good So-so Weak
Weak
Does it make a profit?
β$22.1M
No. It lost money last year.
For information
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Key numbers, fiscal 2026
Market cap
Last close times the latest diluted share count, so it is approximate.
$10.4M
Oct 27 close
P/E
Last close divided by diluted earnings per share over the last four quarters.
β
On β$3.05 EPS (TTM)
Charts by
Sales and profit
Is it selling more, and how much does it keep?
Revenue and margins
Revenue
FY17
Revenue β
FY18
Revenue β
FY19
Revenue β
FY20
Revenue β
FY21
Revenue β
FY22
Revenue β
FY23
Revenue β
FY24
Revenue β
FY25
Revenue β
FY26
Revenue β
Margins, % of revenue
FY17
Gross β
Operating β
Net β
FCF β
FY18
Gross β
Operating β
Net β
FCF β
FY19
Gross β
Operating β
Net β
FCF β
FY20
Gross β
Operating β
Net β
FCF β
FY21
Gross β
Operating β
Net β
FCF β
FY22
Gross β
Operating β
Net β
FCF β
FY23
Gross β
Operating β
Net β
FCF β
FY24
Gross β
Operating β
Net β
FCF β
FY25
Gross β
Operating β
Net β
FCF β
FY26
Gross β
Operating β
Net β
FCF β
Gross
Operating
Net
FCF
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Net income and earnings per share
Loss periods are shown in red.
KIRA summarises the numbers
-
Biovie Inc. lost $22.1M in fiscal 2026.
Net income
FY17
Net income β$1.3M
FY18
Net income β$2.4M
FY19
Net income β$2.4M
FY20
Net income β$16.7M
FY21
Net income β$130M
FY22
Net income β$26.1M
FY23
Net income β$50.3M
FY24
Net income β$32.1M
FY25
Net income β$17.5M
FY26
Net income β$22.1M
Net income
Q1 '24
Net income β$10.7M
Q2 '24
Net income β$8.4M
Q3 '24
Net income β$8.1M
Q4 '24
Net income β$4.9M
Q1 '25
Net income β$4.2M
Q2 '25
Net income β$7.1M
Q3 '25
Net income β$2.8M
Q4 '25
Net income β$3.5M
Q1 '26
Net income β$5.1M
Q2 '26
Net income β$6.1M
Q3 '26
Net income β$5.3M
Q4 '26
Net income β$5.6M
Diluted EPS
FY17
Diluted EPS β$0.01
FY18
Diluted EPS β$0.03
FY19
Diluted EPS β$0.98
FY20
Diluted EPS β$6.85
FY21
Diluted EPS β$14.82
FY22
Diluted EPS β$1.06
FY23
Diluted EPS β$15.47
FY24
Diluted EPS β$73.05
FY25
Diluted EPS β$12.12
FY26
Diluted EPS β$3.05
Diluted EPS
Q1 '24
Diluted EPS β$2.92
Q2 '24
Diluted EPS β$2.20
Q3 '24
Diluted EPS β$2.00
Q4 '24
Diluted EPS β$65.93
Q1 '25
Diluted EPS β$7.00
Q2 '25
Diluted EPS β$4.55
Q3 '25
Diluted EPS β$1.51
Q4 '25
Diluted EPS $0.94
Q1 '26
Diluted EPS β$0.98
Q2 '26
Diluted EPS β$0.77
Q3 '26
Diluted EPS β$0.70
Q4 '26
Diluted EPS β$0.60
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Cash and shareholders
How much cash comes in, and where does it go?
Cash flow
Cash from operations minus capital spending.
Free cash flow
FY17
Free cash flow β
FY18
Free cash flow β
FY19
Free cash flow β
FY20
Free cash flow β
FY21
Free cash flow β
FY22
Free cash flow β
FY23
Free cash flow β
FY24
Free cash flow β
FY25
Free cash flow β
FY26
Free cash flow β
Cash from operations vs capital spending
FY17
Cash from operations β$0.6M
Capital spending β
FY18
Cash from operations β$0.6M
Capital spending β
FY19
Cash from operations β$2.5M
Capital spending β
FY20
Cash from operations β$1.6M
Capital spending β
FY21
Cash from operations β$10.5M
Capital spending β
FY22
Cash from operations β$19.0M
Capital spending β
FY23
Cash from operations β$40.3M
Capital spending β
FY24
Cash from operations β$27.9M
Capital spending β
FY25
Cash from operations β$19.0M
Capital spending β
FY26
Cash from operations β$19.0M
Capital spending β
Cash from operations
Capital spending
Cash from operations vs capital spending
Q1 '24
Cash from operations β$12.2M
Capital spending β
Q2 '24
Cash from operations β$5.9M
Capital spending β
Q3 '24
Cash from operations β$5.9M
Capital spending β
Q4 '24
Cash from operations β$4.0M
Capital spending β
Q1 '25
Cash from operations β$3.6M
Capital spending β
Q2 '25
Cash from operations β$8.6M
Capital spending β
Q3 '25
Cash from operations β$1.3M
Capital spending β
Q4 '25
Cash from operations β$5.6M
Capital spending β
Q1 '26
Cash from operations β$3.0M
Capital spending β
Q2 '26
Cash from operations β$4.4M
Capital spending β
Q3 '26
Cash from operations β$7.4M
Capital spending β
Q4 '26
Cash from operations β$4.1M
Capital spending β
Cash from operations
Capital spending
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Dividends, buybacks and share count
Dividends and buybacks
FY17
Dividends β
Buybacks β
FY18
Dividends β
Buybacks β
FY19
Dividends β
Buybacks β
FY20
Dividends β
Buybacks β
FY21
Dividends β
Buybacks β
FY22
Dividends β
Buybacks β
FY23
Dividends β
Buybacks β
FY24
Dividends β
Buybacks β
FY25
Dividends β
Buybacks β
FY26
Dividends β
Buybacks β
Dividends
Buybacks
Diluted shares outstanding (annual)
FY17
Diluted shares 0.09B
FY18
Diluted shares 0.10B
FY19
Diluted shares 0.00B
FY20
Diluted shares 0.00B
FY21
Diluted shares 0.01B
FY22
Diluted shares 0.02B
FY23
Diluted shares 0.00B
FY24
Diluted shares 0.00B
FY25
Diluted shares 0.00B
FY26
Diluted shares 0.01B
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
KIRA summarises the numbers
-
In the last 12 months, insiders bought $0.0M of shares on the open market and sold none.
Bought, 12 months
$0.0M
4 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 28, 2026 | Amy Suzon ChappellDirector | Bought | 727 | $2.16 | $0.0M | Form 4 |
| Aug 28, 2026 | Joanne Wendy KimChief Financial Officer | Bought | 2,500 | $2.18 | $0.0M | Form 4 |
| Aug 28, 2026 | Joseph M PalumboChief Medical Officer | Bought | 4,843 | $2.16 | $0.0M | Form 4 |
| Aug 27, 2026 | Cuong Do VPresident & CEO, Director | Bought | 15,210 | $2.08 | $0.0M | Form 4 |
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Financial health
Can it carry its debts, and how well does it use its money?
Balance sheet
Cash, debt and the ratios that show how comfortably Biovie Inc. can carry it.
Cash vs debt (incl. leases)
FY17
Cash $0.0M
Debt β
FY18
Cash $0.0M
Debt β
FY19
Cash $0.3M
Debt β
FY20
Cash $0.0M
Debt $0.1M
FY21
Cash $4.5M
Debt β
FY22
Cash $18.6M
Debt β
FY23
Cash $19.5M
Debt β
FY24
Cash $23.8M
Debt β
FY25
Cash $17.5M
Debt β
FY26
Cash $9.0M
Debt β
Cash
Debt
| Fiscal year end | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash and short-term investments | $18.6M | $19.5M | $23.8M | $17.5M | $9.0M |
| Interest coverage | β12.6x | β10.5x | β11.1x | β54.3x | β1,265.5x |
| Current ratio | 4.5x | 2.3x | 2.6x | 9.1x | 3.6x |
| Quick ratio | 4.5x | 2.3x | 2.6x | 9.1x | 3.6x |
| Total assets | $20.1M | $35.1M | $25.2M | $21.6M | $14.3M |
| Total liabilities | $16.4M | $19.8M | $9.7M | $2.6M | $4.0M |
| Shareholders' equity | $3.7M | $15.3M | $15.5M | $19.0M | $10.3M |
| Net debt (β = net cash) | β | β | β | β | β |
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Return on capital, equity and assets (annual)
FY17
Return on capital β
Return on equity β115.0%
Return on assets β56.3%
FY18
Return on capital β
Return on equity β383.8%
Return on assets β107.2%
FY19
Return on capital β
Return on equity β218.0%
Return on assets β102.9%
FY20
Return on capital β
Return on equity β
Return on assets β716.0%
FY21
Return on capital β
Return on equity β
Return on assets β3,203.9%
FY22
Return on capital β
Return on equity β598.2%
Return on assets β199.4%
FY23
Return on capital β
Return on equity β528.7%
Return on assets β182.0%
FY24
Return on capital β
Return on equity β208.3%
Return on assets β106.5%
FY25
Return on capital β
Return on equity β101.6%
Return on assets β75.0%
FY26
Return on capital β
Return on equity β150.8%
Return on assets β123.3%
Return on capital
Return on equity
Return on assets
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
| Test | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | β / 6 | β / 6 | β / 6 | β / 6 | β / 6 | β / 6 | β / 6 | β / 6 | β / 6 |
| Accruals ratio | β29.9% | β79.9% | 2.4% | β646.1% | β2,946.8% | β54.2% | β36.2% | β13.8% | 6.3% | β17.0% |
| Altman Z'' | β8.37 | β18.01 | β10.08 | β146.58 | β265.43 | β44.78 | β32.14 | β46.30 | β45.44 | β89.06 |
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
All figures
Every number, year by year.
10 years of figures
Amounts in USD. Hover a ratioβs name for its definition.
| Fiscal year | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Research and development | $0.5M | $0.4M | $1.0M | $1.2M | $2.5M | $17.3M | $33.3M | $23.1M | $9.3M | $14.0M |
| Operating income | β$1.6M | β$2.4M | β$2.5M | β$2.7M | β$138M | β$27.3M | β$45.1M | β$32.2M | β$18.1M | β$22.7M |
| Interest expense | β | $0.0M | $0.0M | $4.8M | $0.6M | $2.2M | $4.3M | $2.9M | $0.3M | $0.0M |
| Net income | β$1.3M | β$2.4M | β$2.4M | β$16.7M | β$130M | β$26.1M | β$50.3M | β$32.1M | β$17.5M | β$22.1M |
| Net income to common | β | β | β | β | β | β$26.1M | β$50.3M | β$33.0M | β | β |
| Diluted EPS | β$0.01 | β$0.03 | β$0.98 | β$6.85 | β$14.82 | β$1.06 | β$15.47 | β$73.05 | β$12.12 | β$3.05 |
| Diluted shares | 0.09B | 0.10B | 0.00B | 0.00B | 0.01B | 0.02B | 0.00B | 0.00B | 0.00B | 0.01B |
| Cash flow | ||||||||||
| Cash from operations | β$0.6M | β$0.6M | β$2.5M | β$1.6M | β$10.5M | β$19.0M | β$40.3M | β$27.9M | β$19.0M | β$19.0M |
| Stock-based compensation | β | $0.2M | $0.1M | $0.0M | $3.0M | $5.8M | $4.2M | $2.8M | $1.2M | $2.3M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $0.0M | $0.0M | $0.3M | $0.0M | $4.5M | $18.6M | $19.5M | $23.8M | $17.5M | $9.0M |
| Total debt | β | β | β | $0.1M | β | β | β | β | β | β |
| Current assets | $0.0M | $0.0M | $0.7M | $0.4M | $4.6M | $18.8M | $34.0M | $24.0M | $20.7M | $13.6M |
| Current liabilities | $0.6M | $1.2M | $0.4M | $23.5M | $1.0M | $4.2M | $14.5M | $9.4M | $2.3M | $3.8M |
| Goodwill | $0.3M | $0.3M | $0.3M | $0.3M | $0.3M | $0.3M | $0.3M | $0.3M | $0.3M | $0.3M |
| Intangible assets | $2.0M | $1.8M | $1.6M | $1.3M | $1.1M | $0.9M | $0.6M | $0.4M | $0.2M | β |
| Total assets | $2.4M | $2.2M | $2.6M | $2.1M | $6.0M | $20.1M | $35.1M | $25.2M | $21.6M | $14.3M |
| Total liabilities | $1.2M | $2.1M | $0.4M | $23.6M | $1.0M | $16.4M | $19.8M | $9.7M | $2.6M | $4.0M |
| Shareholders' equity | $1.2M | $0.1M | $2.1M | β$21.5M | $5.1M | $3.7M | $15.3M | $15.5M | $19.0M | $10.3M |
| Returns | ||||||||||
| Return on capital employed | β89.6% | β253.1% | β117.2% | 12.6% | β2,733.6% | β170.9% | β218.7% | β202.9% | β93.7% | β216.7% |
| Return on equity | β115.0% | β383.8% | β218.0% | β | β | β598.2% | β528.7% | β208.3% | β101.6% | β150.8% |
| Return on assets | β56.3% | β107.2% | β102.9% | β716.0% | β3,203.9% | β199.4% | β182.0% | β106.5% | β75.0% | β123.3% |
| Return on tangible equity | β | β | β1,060.0% | β | β3,609.2% | β1,060.9% | β350.0% | β223.7% | β94.9% | β222.4% |
| Growth | ||||||||||
| Share count change | β | 7.1% | β97.3% | 94.1% | 151.6% | 98.8% | β86.8% | β86.1% | 226.9% | 390.4% |
| Financial health | ||||||||||
| Interest coverage | β | β57.9x | β8,322.0x | β0.6x | β246.7x | β12.6x | β10.5x | β11.1x | β54.3x | β1,265.5x |
| Current ratio | 0.0x | 0.0x | 1.5x | 0.0x | 4.6x | 4.5x | 2.3x | 2.6x | 9.1x | 3.6x |
| Quick ratio | 0.0x | 0.0x | 1.5x | 0.0x | 4.6x | 4.5x | 2.3x | 2.6x | 9.1x | 3.6x |
| Quality scores | ||||||||||
| Altman Z'' | β8.4 | β18.0 | β10.1 | β146.6 | β265.4 | β44.8 | β32.1 | β46.3 | β45.4 | β89.1 |
| Accruals ratio | β29.9% | β79.9% | 2.4% | β646.1% | β2,946.8% | β54.2% | β36.2% | β13.8% | 6.3% | β17.0% |
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
Source: SEC EDGAR XBRL filings (CIK 0001580149). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.